MYD88 L265P — Targeted Therapies, Trials & Pipeline

The MYD88 L265P activating mutation (present in >90% of Waldenström’s macroglobulinemia) drives NF-κB signaling and predicts sensitivity to BTK inhibition; concurrent CXCR4 mutation modulates depth and speed of response.